FDA Clears SPRINT Peripheral Nerve Stimulation for Chronic Pain

The Food and Drug Administration has cleared the SPRINT Peripheral Nerve Stimulation (PNS) System, maker SPR medicine proclaimed.

"The FDA's clearance comes at a important time once physicians, patients and therefore the U.S. tending system square measure seeking therapies to manage pain whereas reducing opioid use," The SPRINT PNS System includes a thready, convoluted wire, or lead, and a matchbox sized wearable stimulator, regarding the burden of 4 quarters. The lead is placed percutaneously, or through the skin, via a fine needle and connects outwardly to the wearable simulator. The stimulator delivers electrical stimulation through the lead that activates peripheral nerves to realize pain relief. SPRINT is exclusive therein it permits lead placement as so much as 2 to a few centimeters from the targeted nerve. This simplifies the lead placement procedure for physicians and provides them the distinct ability to preferentially stimulate specific fibers of the nerve to maximize pain relief. This innovative approach to PNS is fully reversible, because the device is meant to be withdrawn while not surgery at the top of the 30­ day treatment amount. "SPRINT brings the advantages of PNS to physicians seeking safe and effective alternatives to opioids within the treatment of chronic and acute pain," aforementioned Peter Staats, MD, Master in Business and immediate past president of the Yankee Society of Interventional Pain Physicians.

A medical man will place the system throughout a brief patient procedure while with no surgery or anesthesia. As a result of SPRINT is minimally invasive and utterly reversible, physicians might use it earlier during a patient's treatment method in a trial to cut back or eliminate the necessity for opiates and to avoid expensive alternatives in managing acute and chronic pain. SPRINT is a vital step in providing a drug free medical care particularly since a dressing Clinic report last year declared nearly twenty five percent of patients United Nations agency begin opioids for pain relief get to episodic or long-term use. Multiple clinical trials evaluating SPRINT have incontestable its ability to cut back pain and improve quality of life. In one study funded by the National

An institute of Health, use of SPR’s system was related to a seventy two p.c reduction in average pain. SPR can still sponsor clinical trials to more expand into specific indications.

SPRINT could be a minimally invasive, non opioid, PNS system designed to supply relief for acute and chronic pain, in step with SPR medicine. The system consists of a filiform lead and a matchbox-sized wearable stimulator. The lead is placed percutaneously with a fine needle, and electrical stimulation is delivered through the result in activate the peripheral nerves to attain pain relief. The SPRINT system simplifies the lead placement procedure and permits physicians to focus on specific fibers: Lead placement is as so much as three cm from the targeted nerve, in step with the manufacturer.

“SPRINT brings the advantages of PNS to physicians seeking safe and effective alternatives to opioids within the treatment of chronic and acute pain,” aforesaid Peter Staats, MD, MBA, a right away past president of the yank Society of Interventional Pain Physicians, during a release. “Unlike all alternative PNS systems, SPRINT doesn't need permanent implantation that ought to cut back invasiveness, risk and value.”